Paper28480503
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
Checchio T and 11 others. Clin Pharmacol Ther, 2017. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis. Papers, record 28480503. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28480503
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Models, Statistical | Major topic |
| Piperidines | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Psoriasis | Major topic |
| Pyrimidines | Major topic |
| Pyrroles | Major topic |
| Dose-Response Relationship, Drug | |
| Humans | |
| Severity of Illness Index | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12111919 | Quantifying heterogeneity in a meta-analysis. | Stat Med | 2002 | https://conductscience.org/library/papers/12111919 | PubMed |
| 2 | 24033851 | Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. | J Eur Acad Dermatol Venereol | 2014 | https://conductscience.org/library/papers/24033851 | PubMed |
| 3 | 25455503 | Treatment goals for psoriasis: Should PASI 90 become the standard of care? | Actas Dermosifiliogr | 2015 | https://conductscience.org/library/papers/25455503 | PubMed |
| 4 | 21306785 | Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. | J Am Acad Dermatol | 2011 | https://conductscience.org/library/papers/21306785 | PubMed |
| 5 | 11781126 | A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. | J Clin Epidemiol | 2002 | https://conductscience.org/library/papers/11781126 | PubMed |
| 6 | 15383414 | Bias due to aggregation of individual covariates in the Cox regression model. | Am J Epidemiol | 2004 | https://conductscience.org/library/papers/15383414 | PubMed |
| 7 | 15872205 | Psoriasis. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15872205 | PubMed |
| 8 | 26149717 | Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. | Br J Dermatol | 2015 | https://conductscience.org/library/papers/26149717 | PubMed |
| 9 | 20358280 | Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. | J Pharmacokinet Pharmacodyn | 2010 | https://conductscience.org/library/papers/20358280 | PubMed |
| 10 | 26051365 | Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. | Lancet | 2015 | https://conductscience.org/library/papers/26051365 | PubMed |
| 11 | 25418186 | Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. | Br J Dermatol | 2015 | https://conductscience.org/library/papers/25418186 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42692517 | Quantitative evaluations of time-course and effectiveness of systemic treatments for atopic dermatitis: protocol for a pharmacodynamic model-based meta-analysis. | BMJ Open | 2026 | https://conductscience.org/library/papers/42692517 | PubMed |
| 39245866 | Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/39245866 | PubMed |
| 36947282 | Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. | J Pharmacokinet Pharmacodyn | 2023 | https://conductscience.org/library/papers/36947282 | PubMed |
| 35955723 | VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35955723 | PubMed |
| 35799700 | Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis. | Front Pediatr | 2022 | https://conductscience.org/library/papers/35799700 | PubMed |
| 35174432 | Applications of Model-Based Meta-Analysis in Drug Development. | Pharm Res | 2022 | https://conductscience.org/library/papers/35174432 | PubMed |
| 34276352 | Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34276352 | PubMed |
| 31544068 | Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology. | Indian Dermatol Online J | 2019 | https://conductscience.org/library/papers/31544068 | PubMed |
| 31502263 | Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/31502263 | PubMed |
| 31013000 | Modelling time-course relationships with multiple treatments: Model-based network meta-analysis for continuous summary outcomes. | Res Synth Methods | 2019 | https://conductscience.org/library/papers/31013000 | PubMed |
| 30188571 | Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. | Br J Dermatol | 2019 | https://conductscience.org/library/papers/30188571 | PubMed |
| 29569841 | Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses. | CPT Pharmacometrics Syst Pharmacol | 2018 | https://conductscience.org/library/papers/29569841 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD2 | 914 | PubTator's text mining | https://conductscience.org/library/genes/914 | NCBI Gene |
| IL17A | 3605 | PubTator's text mining | https://conductscience.org/library/genes/3605 | NCBI Gene |
| PDE4A | 5141 | PubTator's text mining | https://conductscience.org/library/genes/5141 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28480503
GET https://conductscience.org/api/papers/v1/28480503/authors